Holen Sie sich die Stockscreener-App
25.05
3.34%
0.81
Vorhandelsmarkt:
23.81
-1.24
-4.95%
Schlusskurs vom Vortag:
$24.24
Offen:
$23.675
24-Stunden-Volumen:
20.59M
Relative Volume:
0.59
Marktkapitalisierung:
$5.80B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
47.98
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
-11.39%
1M Leistung:
+3.13%
6M Leistung:
-32.26%
1J Leistung:
-57.24%
1-Tages-Spanne:
$23.53
$25.32
1-Wochen-Bereich:
$23.26
$30.39
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
25.05 | 5.61B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
16.61 | 52.55B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.29 | 41.12B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.96 | 39.50B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
74.22 | 31.64B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.58 | 24.44B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
4 stocks to watch on Monday: ARM, M, HIMS, INTC - Seeking Alpha
Hims & Hers to Offer $300 Million in Convertible Senior Notes - marketscreener.com
Hims & Hers plans $300 million convertible notes offering - Investing.com India
Hims & Hers plans $300 million convertible notes offering By Investing.com - Investing.com Canada
Hims & Hers stock falls 7% on convertible notes offering plan - Investing.com Canada
Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment - HIMS Investor Relations
Hims & Hers Health Announces Proposed Convertible Senior Notes Offering To Support International Expansion And Accelerate AI-Driven Platform Investment - TradingView
Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment - Business Wire
Earnings call transcript: Hims & Hers Q1 2026 reveals EPS miss, stock drops - Investing.com Canada
+3.34% for Hims & Hers Health stock as renewed demand lifts price from recent lows - Traders Union
5 Revealing Analyst Questions From Hims & Hers Health’s Q1 Earnings Call - TradingView
Spotting Winners: Hims & Hers Health (NYSE:HIMS) And Healthcare Technology Stocks In Q1 - TradingView
Hims & Hers Health, Inc. (HIMS) Investigation: Bronstein, Gewirtz - The National Law Review
Hims & Hers Health: GLP-1 Drama Ending Signals Return To Growth (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health, Inc. Class A Trade Ideas — HAM:82W - TradingView
Hims & Hers breaks further below key technical level after earnings miss - MSN
HIMS Stock | Hims & Hers Health Price, Quote, News & Analysis - TipRanks
Susquehanna entities report 14,502,395 HIMS shares (HIMS) - Stock Titan
HIMS Stock Dips 14.3% Since Q1 Earnings: Should You Still Hold or Sell? - The Globe and Mail
HIMS Q1 Deep Dive: Strategic Pivot in Weight Loss and Margin Pressures Shape Outlook - Yahoo Finance
Hims & Hers Health: The Stock Is On Sale, Buy It (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Hims & Hers Stock Drops After Earnings: Buying Opportunity or Warning Sign? - Yahoo Finance
Hims & Hers Stock Drops After Earnings: Buying Opportunity or Warning Sign? - The Motley Fool
Hims & Hers Health stock holds steady as net loss replaces prior year profit - Traders Union
Investor relations - HIMS Investor Relations
Hims & Hers (NASDAQ: HIMS) — Capital World Investors reports a 2-share holding - Stock Titan
Is Hims and Hers Health Stock a Buy After Its Latest Dip? - The Motley Fool
Hims & Hers Health Is Likely Dead Money (NYSE:HIMS) - Seeking Alpha
Hims & Hers Bets Big on GLP-1 Drugs, But Investors Want Profits Now - Barchart.com
Selling pressure pushes Hims & Hers Health stock lower in today's trading - Traders Union
Biggest stock movers Tuesday: PLUG, HIMS, and more - MSN
Large net loss pushes Hims & Hers Health stock down 3.56% - Traders Union
HIMS Stock Crashes Overnight After Brutal Q1 — But An Investor Says Novo, Lilly Deals Could Make It ‘Netflix Of Healthcare’ - Stocktwits
Hims & Hers expands DTC platform to broaden access to personal care - MSN
Is Hims & Hers Health Inc (HIMS) a Bargain After 3.6% Drop? GF V - GuruFocus
Hims & Hers Health Options Spot-On: On May 13th, 165.49K Contracts Were Traded, With 1.24 Million Open Interest - Moomoo
HIMS stock loses weight: CEO's massive 272x pay gap with workers tips the scales ahead of shareholder vote - MSN
(HIMS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
BofA Cuts Hims & Hers Price Target as Mixed Quarter Resets Street Expectations - AOL.com
Hims & Hers breaks further below key technical level after earnings miss (HIMS:NYSE) - Seeking Alpha
Hims & Hers Health: The Market Is Selling The Wrong Quarter (NYSE:HIMS) - Seeking Alpha
PPI Report April 2026: How Inflation Data Is Moving HIMS, CEG, and PLUG Stock Today - TradingKey
Hims & Hers Health (NYSE:HIMS) Price Target Lowered to $30.00 at Bank of America - MarketBeat
HIMS Maintained by B of A Securities -- Price Target Lowered to $30 - GuruFocus
Compounded GLP-1 write-down drives Hims & Hers Health stock lower by 14.10% - Traders Union
Hims & Hers Health (HIMS) Reports Q1: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Hims & Hers Earnings Call Balances Pain With Growth - TipRanks
Hims & Hers winning bullish views despite Q1 miss - MSN
This Week's Healthcare Earnings: Novo, Hims And More - Law360
Hims & Hers Health: The Real Story Begins (NYSE:HIMS) - Seeking Alpha
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
8.23%
0.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):